Name | Valacyclovir hydrochloride |
Description | Valacyclovir hydrochloride (Valaciclovir hydrochloride) is an acyclovir prodrug that, upon metabolism, inhibits viral DNA replication. |
In vitro | In male CD rats, Valaciclovir was absorbed orally, efficiently metabolized and rapidly distributed. |
In vivo | Valaciclovir is the L-valine ester of aciclovir, the absorption of which occurs in the intestinal lumen and is converted to the L-valine ester of aciclovir.Valaciclovir inhibits the uptake of dipeptide transporter protein substrates, e.g., cephalosporin. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 55 mg/mL (152.44 mM), Sonication is recommended.
|
Keywords | Valacyclovir hydrochloride | Valacyclovir Hydrochloride | Valacyclovir | Valaciclovir Hydrochloride | Valaciclovir | RNASynthesis | RNA Synthesis | Inhibitor | inhibit | HSV | Herpes simplex virus | DNASynthesis | DNA Synthesis | DNA polymerase | Antibiotic |
Inhibitors Related | Neomycin sulfate | 5-Fluorouracil | Ampicillin sodium | Doxycycline (hyclate) | Kanamycin sulfate | Sulfamethoxazole sodium | Guanidine hydrochloride | Metronidazole | Doxycycline | Oxyresveratrol | EDTA copper(II) disodium salt | Thymidine |
Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-COVID-19 Compound Library | Anti-Cancer Drug Library |